Cargando…
Plasma xanthine oxidoreductase activity in patients with decompensated acute heart failure requiring intensive care
AIMS: Plasma xanthine oxidoreductase (XOR) activity during the acute phase of acute heart failure (AHF) requires further elucidation. METHODS AND RESULTS: One hundred eighteen AHF patients and 231 control patients who attended a cardiovascular outpatient clinic were prospectively analysed. Blood sam...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437423/ https://www.ncbi.nlm.nih.gov/pubmed/30620450 http://dx.doi.org/10.1002/ehf2.12390 |
_version_ | 1783406945284128768 |
---|---|
author | Okazaki, Hirotake Shirakabe, Akihiro Matsushita, Masato Shibata, Yusaku Sawatani, Tomofumi Uchiyama, Saori Tani, Kennichi Murase, Takayo Nakamura, Takashi Takayasu, Tsutomu Asano, Miwako Kobayashi, Nobuaki Hata, Noritake Asai, Kuniya Shimizu, Wataru |
author_facet | Okazaki, Hirotake Shirakabe, Akihiro Matsushita, Masato Shibata, Yusaku Sawatani, Tomofumi Uchiyama, Saori Tani, Kennichi Murase, Takayo Nakamura, Takashi Takayasu, Tsutomu Asano, Miwako Kobayashi, Nobuaki Hata, Noritake Asai, Kuniya Shimizu, Wataru |
author_sort | Okazaki, Hirotake |
collection | PubMed |
description | AIMS: Plasma xanthine oxidoreductase (XOR) activity during the acute phase of acute heart failure (AHF) requires further elucidation. METHODS AND RESULTS: One hundred eighteen AHF patients and 231 control patients who attended a cardiovascular outpatient clinic were prospectively analysed. Blood samples were collected within 15 min of admission from AHF patients (AHF group) and control patients who visited a daily cardiovascular outpatient clinic (control group). Plasma XOR activity was compared between the two groups, and factors independently associated with extremely elevated XOR activity were identified using a multivariate logistic regression model. Plasma XOR activity in the AHF group (median, 104.0 pmol/h/mL; range, 25.9–423.5 pmol/h/mL) was significantly higher than that in the control group (median, 45.2 pmol/h/mL; range, 19.3–98.8 pmol/h/mL). The multivariate logistic regression model showed that serum uric acid (per 1.0 mg/dL increase, odds ratio: 1.280; 95% confidence interval: 1.066–1.536; P = 0.008) and lactate levels (per 1.0 mmol/L increase, odds ratio: 1.239; 95% confidence interval: 1.040–1.475; P = 0.016) were independently associated with high plasma XOR activity (>300 pg/h/mL) during the acute phase of AHF. CONCLUSIONS: Plasma XOR activity was extremely high in patients with severely decompensated AHF. This would be associated with a high lactate value and would eventually lead to hyperuricaemia in patients with AHF. |
format | Online Article Text |
id | pubmed-6437423 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-64374232019-04-10 Plasma xanthine oxidoreductase activity in patients with decompensated acute heart failure requiring intensive care Okazaki, Hirotake Shirakabe, Akihiro Matsushita, Masato Shibata, Yusaku Sawatani, Tomofumi Uchiyama, Saori Tani, Kennichi Murase, Takayo Nakamura, Takashi Takayasu, Tsutomu Asano, Miwako Kobayashi, Nobuaki Hata, Noritake Asai, Kuniya Shimizu, Wataru ESC Heart Fail Original Research Articles AIMS: Plasma xanthine oxidoreductase (XOR) activity during the acute phase of acute heart failure (AHF) requires further elucidation. METHODS AND RESULTS: One hundred eighteen AHF patients and 231 control patients who attended a cardiovascular outpatient clinic were prospectively analysed. Blood samples were collected within 15 min of admission from AHF patients (AHF group) and control patients who visited a daily cardiovascular outpatient clinic (control group). Plasma XOR activity was compared between the two groups, and factors independently associated with extremely elevated XOR activity were identified using a multivariate logistic regression model. Plasma XOR activity in the AHF group (median, 104.0 pmol/h/mL; range, 25.9–423.5 pmol/h/mL) was significantly higher than that in the control group (median, 45.2 pmol/h/mL; range, 19.3–98.8 pmol/h/mL). The multivariate logistic regression model showed that serum uric acid (per 1.0 mg/dL increase, odds ratio: 1.280; 95% confidence interval: 1.066–1.536; P = 0.008) and lactate levels (per 1.0 mmol/L increase, odds ratio: 1.239; 95% confidence interval: 1.040–1.475; P = 0.016) were independently associated with high plasma XOR activity (>300 pg/h/mL) during the acute phase of AHF. CONCLUSIONS: Plasma XOR activity was extremely high in patients with severely decompensated AHF. This would be associated with a high lactate value and would eventually lead to hyperuricaemia in patients with AHF. John Wiley and Sons Inc. 2019-01-08 /pmc/articles/PMC6437423/ /pubmed/30620450 http://dx.doi.org/10.1002/ehf2.12390 Text en © 2019 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Research Articles Okazaki, Hirotake Shirakabe, Akihiro Matsushita, Masato Shibata, Yusaku Sawatani, Tomofumi Uchiyama, Saori Tani, Kennichi Murase, Takayo Nakamura, Takashi Takayasu, Tsutomu Asano, Miwako Kobayashi, Nobuaki Hata, Noritake Asai, Kuniya Shimizu, Wataru Plasma xanthine oxidoreductase activity in patients with decompensated acute heart failure requiring intensive care |
title | Plasma xanthine oxidoreductase activity in patients with decompensated acute heart failure requiring intensive care |
title_full | Plasma xanthine oxidoreductase activity in patients with decompensated acute heart failure requiring intensive care |
title_fullStr | Plasma xanthine oxidoreductase activity in patients with decompensated acute heart failure requiring intensive care |
title_full_unstemmed | Plasma xanthine oxidoreductase activity in patients with decompensated acute heart failure requiring intensive care |
title_short | Plasma xanthine oxidoreductase activity in patients with decompensated acute heart failure requiring intensive care |
title_sort | plasma xanthine oxidoreductase activity in patients with decompensated acute heart failure requiring intensive care |
topic | Original Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437423/ https://www.ncbi.nlm.nih.gov/pubmed/30620450 http://dx.doi.org/10.1002/ehf2.12390 |
work_keys_str_mv | AT okazakihirotake plasmaxanthineoxidoreductaseactivityinpatientswithdecompensatedacuteheartfailurerequiringintensivecare AT shirakabeakihiro plasmaxanthineoxidoreductaseactivityinpatientswithdecompensatedacuteheartfailurerequiringintensivecare AT matsushitamasato plasmaxanthineoxidoreductaseactivityinpatientswithdecompensatedacuteheartfailurerequiringintensivecare AT shibatayusaku plasmaxanthineoxidoreductaseactivityinpatientswithdecompensatedacuteheartfailurerequiringintensivecare AT sawatanitomofumi plasmaxanthineoxidoreductaseactivityinpatientswithdecompensatedacuteheartfailurerequiringintensivecare AT uchiyamasaori plasmaxanthineoxidoreductaseactivityinpatientswithdecompensatedacuteheartfailurerequiringintensivecare AT tanikennichi plasmaxanthineoxidoreductaseactivityinpatientswithdecompensatedacuteheartfailurerequiringintensivecare AT murasetakayo plasmaxanthineoxidoreductaseactivityinpatientswithdecompensatedacuteheartfailurerequiringintensivecare AT nakamuratakashi plasmaxanthineoxidoreductaseactivityinpatientswithdecompensatedacuteheartfailurerequiringintensivecare AT takayasutsutomu plasmaxanthineoxidoreductaseactivityinpatientswithdecompensatedacuteheartfailurerequiringintensivecare AT asanomiwako plasmaxanthineoxidoreductaseactivityinpatientswithdecompensatedacuteheartfailurerequiringintensivecare AT kobayashinobuaki plasmaxanthineoxidoreductaseactivityinpatientswithdecompensatedacuteheartfailurerequiringintensivecare AT hatanoritake plasmaxanthineoxidoreductaseactivityinpatientswithdecompensatedacuteheartfailurerequiringintensivecare AT asaikuniya plasmaxanthineoxidoreductaseactivityinpatientswithdecompensatedacuteheartfailurerequiringintensivecare AT shimizuwataru plasmaxanthineoxidoreductaseactivityinpatientswithdecompensatedacuteheartfailurerequiringintensivecare |